Similar articles

• Laminin-1 reexpression in Alport mouse glomerular basement membranes.

  Abrahamson DR, Prettyman AC, Robert B, St John PL. Abrahamson DR, et al. Kidney Int. 2003 Mar;63(3):826-34. doi: 10.1046/j.1523-1755.2003.00800.x. Kidney Int. 2003. PMID: 12631063
• Alport syndrome.

  Kashtan CE. Kashtan CE. Kidney Int Suppl. 1997 Mar;58:S69-71. Kidney Int Suppl. 1997. PMID: 9067948 Review. No abstract available.
• Extracellular Matrix: Alport Syndrome.

  Tsang SH, Sharma T. Tsang SH, et al. Adv Exp Med Biol. 2018;1085:197-198. doi: 10.1007/978-3-319-95046-4_41. Adv Exp Med Biol. 2018. PMID: 30578514 Review.
• Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects.

  Abrahamson DR, Isom K, Roach E, Stroganova L, Zelenchuk A, Miner JH, St John PL. Abrahamson DR, et al. J Am Soc Nephrol. 2007 Sep;18(9):2465-72. doi: 10.1681/ASN.2007030328. Epub 2007 Aug 15. J Am Soc Nephrol. 2007. PMID: 17699809
• Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases), and MT1-MMP in canine X-linked Alport syndrome (XLAS).

  Rao VH, Lees GE, Kashtan CE, Nemori R, Singh RK, Meehan DT, Rodgers K, Berridge BR, Bhattacharya G, Cosgrove D. Rao VH, et al. Kidney Int. 2003 May;63(5):1736-48. doi: 10.1046/j.1523-1755.2003.00939.x. Kidney Int. 2003. PMID: 12675849